MOTIV Bioresorbable Scaffold in BTK Artery Disease (MOTIV BVS BTK)

Physician-initiated Trial Investigating the MOTIV™ Bioresorbable Scaffold (Reva Medical) for the Treatment of Below-The-Knee Artery Disease

The objective of this clinical evaluation is to evaluate the immediate and long-term (up to 36 months) outcome of the MOTIV™ Bioresorbable Scaffold (Reva Medical) in a controlled prospective investigation for the treatment of patients with rest pain or minor tissue loss (CLI) due to the presence of lesions of max 100mm in length at the level of the below-the-knee arteries.

Study Overview

• Status: Active, not recruiting
• Conditions: Peripheral Arterial Disease; Critical Limb Ischemia
• Intervention / Treatment: Device: MOTIV BVS

• Study Type: Interventional
• Enrollment (Actual): 58
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Austria
  • Vienna, Austria
    • Hospital Floridsdorf
• Germany
  • Arnsberg, Germany
    • Klinikum Hochsauerland
  • Bad Oeynhausen, Germany
    • Bad Oeyhausen Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie
  • Berlin, Germany
    • Medizinische Versorgungszentren GmbH
  • Leipzig, Germany
    • University Hospital Leipzig, Angiology
  • Mainz, Germany
    • Katholisches Klinikum Mainz; Akademisches Lehrkrankenhaus der Johannes Gutenberg-Universität Mainz
  • Münster, Germany
    • St. Franziskus-Hospital
  • Münster, Germany
    • University Hospital Münster, Angiology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is willing to comply with specified follow-up evaluations at the specified times
• Patient presenting with rest pain or minor tissue loss (Rutherford classification from 4 to 5)
• Patient is >18 years old
• Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study - Patient has a projected life-expectancy of at least 24-months
• Patient is eligible for treatment with the MOTIV™ Bioresorbable Scaffold
• Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
• De novo lesion or Restenotic lesion after PTA in the infrapopliteal arteries, suitable for endovascular therapy
• Target vessel diameter visually estimated to be ≥2.5mm and ≤3.50mm
• Guidewire and delivery system successfully traversed the lesion
• Total target lesion is maximally 100mm

• Definition of Target Lesion is:

  1. short de novo or Restenotic lesion after PTA or
  2. a short residual flow-limiting dissection or restenosis after PTA of a longer lesion

Exclusion Criteria:

• The reference segment diameter is not suitable for the available stent design
• Untreated flow-limiting aortoiliac stenotic disease
• Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment.
• Any previous surgery in the target vessel
• Aneurysm located at the target vessel
• Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
• Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy.
• Major distal amputation (above the transmetatarsal) in the study or non-study limb.
• Septicemia or bacteremia
• Any previously known coagulation disorder, including hypercoagulability
• Contraindication to anticoagulation or antiplatelet therapy
• Known allergies to scaffold or scaffold components
• Known allergies to contrast media that cannot be adequately premedicated prior to the study procedure
• Patient with known hypersensitivity to heparin-induced thrombocytopenia (HIT) type II
• Currently participating in another clinical research trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MOTIV bioresorbable vascular scaffold; MOTIV bioresorbable vascular scaffold for below-the-knee artery disease	Device: MOTIV BVS; MOTIVS BVS in below-the-knee artery disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
efficacy endpoint - Primary Patency rate at 12-months post-op	Primary patency defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months.	12 months post-op
safety endpoint - rate of serious device-related adverse events within 30 days post-op	Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure.	30 days post-op

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Technical Success	Technical Success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%	1-day post-op
Primary Patency rate at follow-up visits	Primary patency rate defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months.	1 month, 6 months, 12 months, 24 months and 36 months post-op
Clinically-driven target lesion revascularization (TLR) at 1, 6, 12, 24 and 36-months	Clinically-driven (drop in 1 Rutherford Classification) target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the device/PTA edge	1 month, 6 months, 12 months, 24 months and 36 months post-op
Limb-Salvage rate at follow-up visits	Major amputation is defined as amputation at or above the ankle, as opposed to minor amputation, being an amputation at or below metatarsal level, preserving functionality of the foot.	1 month, 6 months, 12 months, 24 months and 36 months post-op
Clinical success at follow-up visits	Clinical success at follow-up is defined as an improvement of Rutherford classification at 1 day and 1-, 6-, 12-, 24- and 36-months follow-up of one class or more as compared to the pre-procedural Rutherford Classification.	1 day post-op and 1 month, 6 months, 12 months, 24 months and 36 months post-op
Serious adverse events during the study (within 36 months post-op)	Serious adverse events as defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.	within 36 months post-op

Collaborators and Investigators

• Sponsor: Dr. Sabrina Overhagen

Study record dates

Study Major Dates

• Study Start (Actual): September 5, 2019
• Primary Completion (Actual): July 1, 2022
• Study Completion (Anticipated): July 1, 2024

Study Registration Dates

• First Submitted: June 12, 2019
• First Submitted That Met QC Criteria: June 12, 2019
• First Posted (Actual): June 14, 2019

Study Record Updates

• Last Update Posted (Actual): March 17, 2023
• Last Update Submitted That Met QC Criteria: March 15, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases
• Other Study ID Numbers: FCRE-190131

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No